Zebrafish shares common metabolic pathways with mammalian olanzapine-induced obesity

Pukar Khanal¹*, B. M. Patil¹* and Banappa. S. Unger²

Abstract

Background: Olanzapine is one of the most prescribed antipsychotic agents in the pharmacotherapy of psychiatric illness; however, it is associated with multiple side effects primarily obesity. Multiple investigations have been made to model the olanzapine-induced obesity in rodent models which was found to be dose-dependent, gender-dependent, and species-dependent. *Danio rerio* is a choice of an animal model to understand the pathogenesis of multiple diseases. The present study dealt to understand the olanzapine-associated obesity in zebrafish using in silico and wet-lab experimental protocols by performing gene set enrichment analysis, phylogeny comparison of receptors, and assessing the effect of olanzapine on metabolic rate, lipid metabolism, body weight, and food intake in zebrafish.

Results: The metabolic pathway was predicted to be majorly modulated by olanzapine in human, rat, mouse, and zebrafish. A clade of receptors of rat, mouse, and human receptor for feeding and satiety center was found similar to zebrafish. The decrease in lipid metabolism was observed in zebrafish larvae if exposed to olanzapine solution. Similarly, there was a significant decrease in metabolic rate in 200 μM and 400 μM concentration of olanzapine.

Conclusion: Enrichment analysis predicted the probable modulation of metabolic pathways in zebrafish if exposed to olanzapine. Further, olanzapine was identified to play a prime role in decreasing lipid metabolism and metabolic rate and increasing food intake and weight gain in zebrafish which suggests the validation of this model for olanzapine-induced obesity.

Keywords: *Danio rerio*, Lipid metabolism, Metabolic rate, Olanzapine-induced obesity, Zebrafish

Background

The current pharmacotherapy of psychiatric illness utilizes many atypical antipsychotic molecules in which olanzapine reserve its own importance in the major portion of prescription due to its high efficacy. However, the molecule is associated with multiple side effects, i.e. diabetes, dyslipidemia, and cardiovascular system (CVS) complications including obesity [1–3]. Many, attempts have been made to understand the mechanism for olanzapine-induced weight gain in various rodent models. However, the effects of olanzapine observed in rodent models were gender-dependent, dose-dependent, and duration-dependent [4–8] reflecting the lack of an adequate model to represent the pathogenesis of olanzapine-induced obesity. Further, rodent models conserve the property of being unwieldy, expensive, and are allied with ethical issues for their utilization in research. This limitation kindled us to identify a new simple and alternative animal model for olanzapine-induced obesity.

*Danio rerio*, commonly identified as zebrafish, is an alternative animal model that has been extensively utilized in biomedical research [9] due to its similarity in physiological and metabolic pathways with *Homo sapiens* and other rodent animal models. Further, it has got popularity in lipid research, mainly for lipoprotein metabolism, lipid absorption and deposition, hepatic
steatosis, obesity, diabetes, and other metabolic disorders [10]. Further, these vertebrates are also reported to share parallel pathophysiological pathways to mammals for diet-induced obesity [11]. These reports kindled us to investigate if olanzapine-induced abnormalities primarily lipid metabolism, metabolic rate, food intake, and weight gain can be expressed in zebrafish or not. To fulfill this hypothesis, we utilized the cheminformatics tools to predict the olanzapine-induced gene expression profile in Homo sapiens, Rattus norvegicus, Mus musculus, and Danio rerio, similarity index of the receptors available in the feeding, and satiety center. Further, the effect of olanzapine on lipid metabolism, metabolic rate, food intake, and weight gain was evaluated via experimental protocols.

Methods
Olanzapine-induced gene expression and gene set enrichment analysis
Canonical SMILES of olanzapine was retrieved from the PubChem database (https://pubchem.ncbi.nlm.nih.gov/) and queried for the probable mRNA-based gene expression using DIGEP-Pred [12]. All the expressed genes with probable activity (Pa) greater than probable inactivity (Pi) were queried in STRING [13] database to evaluate the protein-protein interaction for Homo sapiens, Rattus norvegicus, Mus musculus, and Danio rerio with reference to Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway (https://www.genome.jp/kegg/pathway.html) database.

Phylogenetic comparison of olanzapine-modulated receptors
Proteins modulated by the olanzapine were identified from BindingDB [14] which works based on the principle “similar compounds tend to bind the same proteins” by querying canonical SMILES. The amino acid sequences of protein molecules for Homo sapiens, Rattus norvegicus, Mus musculus, and Danio rerio were retrieved from the NCBI database (https://www.ncbi.nlm.nih.gov/). The accession number of protein molecules subjected to phylogenetic comparisons is summarized in Table 1. Amino acid sequences were aligned using multiple sequence alignment, and the phylogenetic tree was constructed using the UPGMA clustering method. The bootstrap score was used to assess the similarity score between the protein molecules.

Ethical approval and housing of zebrafish
The experiment was performed after receiving ethical clearance from the IAEC, accession number KLECOP/CPCSEAReg.No.221/PO/Re/S/2000/CPCSEA Res.25-09/09/2017. Adult wild zebrafish of 2.5–3.5 cm were purchased from Fish-O-fish aquarium, Nehru Nagar Kurla (E) Mumbai and were housed under 14:10 light/dark photoperiod in a re-circulating aqueous system (water temperature 26 ± 1 °C, dissolved oxygen (measured using dissolved oxygen kit, HighMedia) > 4 mg/L, conductivity 500–650 μS cm⁻¹ (maintained using Red Sea Salt), pH 6.8–7.4, and total dissolved salt (TDS) 250 to 325 ppm) and fed with dry flakes (once) and brine shrimps (twice) daily. Ten percent of total system water was replaced with new RO-purified water to maintain the water condition.

Breeding and maintenance of fertilized embryos
Adult zebrafish were allowed to mate in the ratio of 2:3. Initially, before the beginning of the dark photoperiod, the animals were separated and mixed together just before the beginning of light photoperiod, and fishes are allowed to mate. After 30 to 45 min, the embryos were collected, washed, and maintained in embryo medium (HBSS Sigma). The fish were returned to their cages allowing a week of resting period before two successive breedings. Embryos were washed at 6 and 24 hpf to remove the coagulated embryos; a percentage of coagulated embryos and hatched larvae were recorded at 24 and 72 h, respectively.

Selection of dose
OECD 236 guidelines were followed to perform the fish embryonic toxicity (FET) which identified lethal concentration (LC₅₀:64 μM) and maximum non-lethal concentration (MNLC:50 μM) of olanzapine in 72 hpf larvae. Hence, five different concentrations of olanzapine in geometric series were chosen to evaluate the effect of olanzapine on lipid metabolism and metabolic rate. Further, metabolic rate was evaluated in a broader range of drug concentrations, i.e. below and above the MNLC since the change in metabolic rate was not observed in lower concentrations.

Effect of olanzapine on lipid metabolism in zebrafish larvae
The effect of olanzapine on lipid metabolism was assessed in 72 hpf larvae [15]. Zebrafish larvae were exposed to multiple concentrations of olanzapine for 24 h at 28 °C. After 24 h, larvae were fixed in 4% paraformaldehyde, and Oil Red O (ORO) imaging procedure was performed under a dissecting stereoscopic microscope (Olympus Co., Tokyo, Japan). ORO was then quantified to determine the accumulation of lipids in different parts of larvae. The amount of lipid was quantified using the Fiji (Image J) software under red, green, and blue channels.

Effect of olanzapine in metabolic rate in zebrafish larvae
Whole-body metabolic rate assay [16] was performed to evaluate the effect of olanzapine on metabolic rate with minor modifications. Briefly, 72 hpf zebrafish larvae were
exposed to five different concentrations (200 μM, 100 μM, 50 μM, 25 μM, and 12.5 μM) of olanzapine and assay buffer (0.01% w/v of phenol red in sodium bicarbonate solution at pH 8.0 and conductivity 350 μM) in 96-well microtiter plate, and absorbance was recorded for 180 min at 570 nm at 10 min interval. The amount of acid produced over a period of time was quantified by using a linear regression curve.

**Effect of olanzapine in food intake and weight gain**
Bodyweight was recorded at the interval of 3 days, and food intake (daily) for 21 days using thirty adult female zebrafish weighting 229 ± 20 mg. The study design included five groups, each containing six zebrafish in each: Group 1, exposed to system water; Group 2, to 0.001% DMSO in system water; Group 3, exposed to 16.66 μM olanzapine; Group 4, exposed to 5 μM olanzapine; and Group 5, exposed to 0.5 μM olanzapine. After the completion of the study, all adult zebrafish were allowed to rehabilitate separately with the adequate conditions and not utilized for any other experiments.

**Statistical analysis**
Results were expressed as mean ± SEM. The significant difference among data was determined using one-way ANOVA followed by the Tukey test using the GraphPad Prism software version 5.0. The difference between mean was considered significant if p value < 0.05. The network of gene-pathway interaction was interpreted by edge count. The similarity index between proteins was compared via the bootstrap score using MEGA7.

**Results**
**Olanzapine-induced gene expression and gene set enrichment analysis**
Based on mRNA-based prediction, forty-five genes were predicted to be expressed; among them, twenty were downregulated and twenty-five were upregulated. Gene set enrichment predicted forty-five proteins to be modulated in *Homo sapiens*, forty-three in *Rattus norvegicus* and *Mus musculus*, and thirty-nine in *Danio rerio*. Similarly, SERPINA3 and C10ORF118 were not detected in *Rattus norvegicus* and *Mus musculus* and EVI2B, FNDC4, SERPINA3, CYP2E1, LST1, and NR1H2 in *Danio rerio*. Further, KEGG pathway analysis identified eight pathways to be modulated in *Homo sapiens*, nine in *Rattus norvegicus*, eight in *Mus musculus*, and three in *Danio rerio*. Among all, the metabolic pathway was common and was majorly modulated in all species. Figure 1 summarizes the detail pathway-gene interaction, and Table 2 summarizes the gene set enrichment of individual pathways of each species.

**Phylogenetic comparison of olanzapine-modulated receptors**
Among *Rattus norvegicus*, *Mus musculus*, and *Danio rerio*, receptors of *Rattus norvegicus* and *Mus musculus*...
were more similar to *Homo sapiens* compared to *Danio rerio*. However, M2, 5HT-1A, and alpha 1A receptors of *Rattus norvegicus* were more similar to *Homo sapiens* compared to *Mus musculus*. The phylogenic representation including a bootstrap score of the *Danio rerio* branch with a clade of *Homo sapiens*, *Rattus norvegicus*, and *Mus musculus* is presented in Fig. 2.

**Effect of olanzapine on lipid metabolism**

In 50 μM olanzapine, the natural death of larvae occurred at 192 h of exposure (Fig. 3). Fish embryonic toxicity (FET) also reflected 50 μM olanzapine as a maximum non-lethal concentration. Hence, multiple concentrations of olanzapine, i.e., 50 μM, 25 μM, 12.5 μM, 6.25 μM, and 3.125 μM, were chosen to expose 72-hpf larvae. Accumulation of lipid increased significantly from lowest concentration (3.125 μM, \( p < 0.05 \)) to the highest concentration (50 μM, \( p < 0.001 \)) (Fig. 4) which was quantified by integrated optical density (IOD) of stain; represents the total amount of lipid present in the whole body of larvae.

**Effect of olanzapine on metabolic rate in zebrafish larvae**

Empirical titration was performed by adding a known amount of acid (H⁺) in each well of 96-well microtiter plates and titrated with 50 μl assay buffer (0.01% w/v phenol red). The linear equation \( y = -0.3342x + 2.3768 \) was obtained with \( R^2 \) value of 0.997. Larvae exposed to the range of concentrations of olanzapine modulating lipid metabolism, body weight, and food intake had no significant effect to change the metabolic rate. However, exposure of larvae at higher concentration, i.e., 200 μM and 400 μM of olanzapine, showed a significant change in acid production at different time intervals (Fig. 5). Toxicity of phenol red was evaluated by exposing 72-hpf zebrafish larvae to buffer at pH 8.0 containing phenol red (0.01% w/v). Death of larvae in assay buffer began after the 4th day of exposure. However, log-rank (Mantel-Cox) test showed in significant difference in death in assay buffer compared to system water suggesting that phenol red did not cause any toxic effect during the experiment (Fig. 6).
Effect of olanzapine on food intake and weight gain
Hyperphagia was observed from the 7th day and continued till the 20th day in adult zebrafish exposed to 0.5 μM olanzapine. Similarly, zebrafish exposed to 0.5 μM showed a significant increase in weight gain on the 12th day and continued until the 20th day (Fig. 7).

Discussion
The present study dealt to investigate whether olanzapine-induced metabolic changes can be demonstrated in zebrafish or not which can be further employed as an alternative experimental model. Before the performance of wet-lab experiments, we predicted the olanzapine-induced gene expression in four

Table 2 Olanzapine-induced gene set enrichment analysis in Homo sapiens, Rattus norvegicus, Mus musculus, and Danio rerio

| Organism          | Pathway                        | Description                  | Gene count | Genes                        | False discovery rate |
|-------------------|--------------------------------|------------------------------|------------|------------------------------|----------------------|
| Homo sapiens      | hsa04975                       | Fat digestion and absorption | 2          | FABP1, BCA1                  | 0.0428               |
|                   | hsa04931                       | Insulin resistance           | 3          | SLC2A1, SLC2A4, NR1H2         | 0.0428               |
|                   | hsa04920                       | Adipocytokine signaling pathway | 3          | SLC2A1, SLC2A4, ADIPOQ        | 0.0428               |
|                   | hsa04152                       | AMPK signaling pathway       | 3          | SLC2A4, ADIPOQ, HMGCR         | 0.0428               |
|                   | hsa01100                       | Metabolic pathways           | 9          | ALDH18A1, DHFR, H6PD, LSS, SC5D, HMGCS1, CYP2E1, HMGCR, ASAH1 | 0.0428               |
|                   | hsa00900                       | Terpenoid backbone biosynthesis | 2          | HMGCS1, HMGCR                | 0.0428               |
|                   | hsa01000                       | Steroid biosynthesis         | 2          | LSS, SC5D                    | 0.0428               |
|                   | hsa04920                       | Type II diabetes mellitus    | 2          | SLC2A4, ADIPOQ, HMGCR         | 0.0428               |
| Rattus norvegicus | rno04975                       | Fat digestion and absorption | 2          | FABP1, BCA1                  | 0.0428               |
|                   | rno04931                       | Insulin resistance           | 3          | SLC2A4, NR1H2, SC2A4, LSS, LCA2A1 | 0.0428               |
|                   | rno04920                       | Adipocytokine signaling pathway | 3          | ADIPOQ, SLC2A4, SC2A1         | 0.0428               |
|                   | rno04152                       | AMPK signaling pathway       | 3          | ADIPOQ, SLC2A4, HMGCR         | 0.0428               |
|                   | rno01100                       | Metabolic pathways           | 3          | CYP2E1, HMGCR, SC5D, HMGCS1, LSS, H6PD, DHFR, ASAH1 | 0.0428               |
|                   | rno00900                       | Terpenoid backbone biosynthesis | 2          | HMGCR, HMGCS1                | 0.0428               |
|                   | rno01000                       | Steroid biosynthesis         | 2          | SC5D, LSS                    | 0.0428               |
|                   | rno04975                       | Type II diabetes mellitus    | 2          | ADIPOQ, SLC2A4, HMGCR         | 0.0428               |
| Mus musculus      | mmu04975                       | Fat digestion and absorption | 2          | FABP1, BCA1                  | 0.0428               |
|                   | mmu04931                       | Insulin resistance           | 3          | NR1H2, SLC2A4, SC2A4          | 0.0428               |
|                   | mmu04920                       | Adipocytokine signaling pathway | 3          | ADIPOQ, SLC2A4, SC2A1         | 0.0428               |
|                   | mmu04152                       | AMPK signaling pathway       | 3          | ADIPOQ, SLC2A4, HMGCR         | 0.0428               |
|                   | mmu01100                       | Metabolic pathways           | 9          | ASAH1, CYP2E1, H6PD, HMGCR, DHFR, ALDH18A1, HMGCS1, LSS, SC5D | 0.0428               |
|                   | mmu00900                       | Terpenoid backbone biosynthesis | 2          | HMGCS1, HMGCR                | 0.0428               |
|                   | mmu00100                       | Steroid biosynthesis         | 2          | SC5D, LSS                    | 0.0428               |
|                   | mmu04930                       | Type II diabetes mellitus    | 2          | ADIPOQ, SLC2A4, HMGCR         | 0.0428               |
| Danio rerio       | dre00100                       | Steroid biosynthesis         | 2          | SC5D, LSS                    | 0.0428               |
|                   | dre01100                       | Metabolic pathways           | 7          | SC5D, HMGCS1, LSS, H6PD, DHFR, ALDH18A1, ASAH1 | 0.0428               |

Khanal et al. Future Journal of Pharmaceutical Sciences (2020) 6:36
different species. Interestingly, we identified a metabolic pathway to be common in all, modulating the highest number of gene sets. Further, a clade of proteins involved in feeding and satiety center of Danio rerio, Rattus norvegicus, and Mus musculus was found to be similar with Homo sapiens. This reflected that the receptors present in hunger and satiety center are closely related among four different species; suggested the feeding behavior of Danio rerio could be similar to Homo sapiens, Rattus norvegicus, and Mus musculus. These two observations further kindled us to evaluate the effect of olanzapine in lipid metabolism, metabolic rate, food intake, and weight gain in zebrafish larvae.

Literature reflects that olanzapine-induced obesity is associated with hyperphagia leading to weight gain. This hypothesis of olanzapine-induced obesity has been successively demonstrated in rodent models. In the present study, exposure of adult zebrafish in olanzapine showed an increase in food intake and weight gain in 0.5 μM concentration. Hence, the study was further designed to understand the effect of olanzapine on lipid metabolism in zebrafish larvae.

Further, a correlation has been made between olanzapine-induced obesity and anomalous metabolism of the lipids. An elevated level of free fatty acids, TGs, total cholesterol, LDL, and low level of HDL have been reported in olanzapine-induced obesity directing towards dyslipidemia and its associated complications. Similarly, in the current study, exposure of 72 hpf larvae in the solution of olanzapine for 24 h showed a decrease in lipid metabolism which was confirmed via the Oil Red O staining technique. This altered lipid metabolism in olanzapine-exposed larvae reflects “dwindle lipid metabolism” as one of the important reasons for olanzapine-induced obesity.

**Fig. 2** Phylogeny comparison of receptors present in feeding and satiety center. The number at branching point refers to bootstrap score based on 500 replicates.
The decrease in lipid metabolism is linked with repression in energy expenditure [22] which occurs due to variation in basal metabolic rate [23–25]. This variation of basal metabolic rate is closely related to abnormal metabolism of lipids [26]. Total respiratory compliance is decreased in the obese population compared to the normal population. This reduction in total respiratory compliance is due to increased pulmonary blood volume, decrease in chest wall, and accumulation of fat in and around the ribs, diaphragm, and abdomen. Interestingly, this observation was also recorded in the present study during the assessment of lipid metabolism in zebrafish larvae. Reduction in total respiratory compliance causes an increase in respiratory resistance [26–28] and high anaerobic respiration [26, 29] leading to lactic acidosis reflecting the decreased metabolic rate. Metabolic rate was assessed in zebrafish larvae by utilizing an anaerobic system which is based on the principle of accumulation of lactic and carbonic acid [16]. Larvae exposed to olanzapine showed increased acid production (H⁺) leading to a decrease in basal metabolic rate.

Further, it has been predicted that a single compound can bind/modulate multiple proteins and regulate pathways associated with them [30, 31]. So, there is a possibility that olanzapine can also bind or regulate multiple proteins/pathways related to the homeostasis of appetite and energy expenditure. Hence, further investigation needs to assess the role of olanzapine-modulated proteins/pathways in the development and progression of obesity and other side effects.

**Conclusion**
The gene-set enrichment analysis identified five common genes which are also expressed in human and rodents. However, the role of each gene, i.e. h6pd, dhfr, aldh18a1, asah1a, and hmgcs1, needs to be extensively investigated for olanzapine-induced metabolic abnormalities in zebrafish and other rodent models. However, this predication helped us to identify olanzapine-induced metabolic abnormalities, i.e., decreased lipid metabolism and metabolic rate and increased food intake and body weight. Limiting to the present study, change in the metabolic rate occurred in the toxic concentration of olanzapine, i.e. 400 μM and 200 μM making suspicious for change in metabolic rate due to energy expenditure. Further, approaches should be framed to evaluate biochemical parameters and assess gene expression profiles related to olanzapine-induced obesity in zebrafish using well-designed wet-lab protocols to confirm the current findings.

**Supplementary information**
Supplementary information accompanies this paper at https://doi.org/10.1186/s43094-020-00049-7.

Additional file 1. ARRIVE1
Fig. 4 Effect of olanzapine (50 μM, 25 μM, 12.5 μM, 6.25, and 3.125 μM) in lipid metabolism in zebrafish larvae. Zebrafish at 72 hpf were exposed to C1, system water; C2, 0.0001% v/v DMSO; T1, 3.125 μM; T2, 6.25 μM; T3, 12.5 μM; T4, 25 μM, and T5, 50 μM of olanzapine. Lipids of zebrafish gut and vasculature increased with increase in the concentration of olanzapine. Scale 100 μm. Number of larvae in each groups (n) = 10. All the data are expressed in mean ± SEM. *p < 0.05, **p < 0.01 compared to solvent control.

Fig. 5 Effect of olanzapine (400 μM and 200 μM) on metabolic rate. Data are shown in 30 min interval. All the data are expressed in mean ± SEM. Number of larvae in each group (n) = 8. *p < 0.05, **p < 0.001 significantly different versus solvent group.
**Fig. 6** Survival curve of larvae exposed to buffer in the presence and absence of phenol red. PR, phenol red

**Fig. 7** Effect of olanzapine on 

- **a** food intake and
- **b** body weight. All the data are expressed in mean ± SEM. Number of adult zebrafish in each group ($n = 6$). *$p < 0.05$, **$p < 0.001$ significantly different versus solvent group
Abbreviations
ANOVA: Analysis of variance; CVS: Cardiovascular system; FET: Fish embryonic toxicity; HDL: High-density lipoprotein; IAEC: Institutional Animal Ethics Committee; KEGG: Kyoto Encyclopedia of Genes and Genomes; MNLC: Maximum non-lethal concentration; NCBP: National Centre for Biotechnology Information; OECD: Organisation for Economic Co-operation and Development; ORQ: Oil Red O; Pa: Probable activity; PI: Probable inactivity; SMILES: Simplified molecular-input line-entry system; TDS: Total dissolved salt; UPGMA: Unweighted pair group method with arithmetic mean.

Acknowledgements
The authors are thankful to Apotex Research Private Limited for providing the gift sample of olanzapine, KLE College of Pharmacy for financing the study as intramural research, and ICMR-NITM Belagavi for providing the necessary facilities throughout the study.

Authors’ contributions
PK contributed in experimental design for in silico study, performed the wet-lab experiment, and drafted the manuscript. BMP introduced a concept for utilizing zebrafish in olanzapine-induced obesity in zebrafish and reviewed the manuscript. BSU provided the necessary facilities for the experimental work, trained PK in developing the skills in zebrafish experiments and contributed in drafting the manuscript. All authors read and approved the final manuscript.

Availability of data and materials
The data for this work are available with Pukar Khanal upon request.

Funding
This work has not received any funding from any National and International agencies.

Competing interests
The authors declared no conflict of interest.

Author details
1Department of Pharmacology and Toxicology, KLE College of Pharmacy, KLE Academy of Higher Education and Research (KAHER), Belagavi 590010, India. 2Division of Pharmacology and Toxicology, Indian Council of Medical Research-National Institute of Traditional Medicine (ICMR-NITM), Belagavi 590010, India.

Received: 11 November 2019 Accepted: 30 June 2020
Published online: 23 July 2020

References
1. Lord CC, Wyler SC, Wan R, Castorena CM, Ahmed N, Mathew D, Lee S, Liu C, Elmqist JK (2017) The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C. J Clin Invest 127(9):3402–3406. https://doi.org/10.1172/JCI93562
2. Redinger RN (2007) The pathophysiology of obesity and its clinical manifestations. Gastroenterol Hepatol 3(1):856. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104148/pdf/GH-03-856.pdf
3. Cooper GD, Pickavance LC, Wilding JP, Halford JC, Goudie AJ (2005) A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology (Berl) 181(1):80–89. https://doi.org/10.1007/s00213-005-2224-4
4. Shah R, Subhan F, Ali G, Ullah I, Ullah S, Shahid M, Ahmad N, Nawad K (2016) Olanzapine induced biochemical and histopathological changes after its chronic administration in rats. Saudi Pharm J 24(6):698–704. https://doi.org/10.1016/j.jspj.2015.06.006
5. Pouzet B, Mow T, Krieglaard M, Velschow S (2003) Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol Biochem Behav 75(1):133–140. https://doi.org/10.1016/S0091-3057(03)00042-x
6. Choi S, DiSilvio B, Ursunt J, Ferronmo JD (2007) Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats. Life Sci 81(12):1024–1030. https://doi.org/10.1016/j.lfs.2007.08.009
7. Davey KJ, O’Mahony SM, Schellekens H, O’Sullivan Q, Bienenstock J, Cotter PD, Dinan TG, Cryan JF (2012) Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters. Psychopharmacology (Berl) 221(1):155–169. https://doi.org/10.1007/s00213-011-2555-2
8. Albaugh VL, Henry CR, Bello NT, Hajnal A, Lynch SL, Halle B, Lynch CJ (2006) Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity (Silver Spring) 14(1):36–51. https://doi.org/10.1038/oby.2006.6
9. Brittijn SA, Duvestein SJ, Belnamoure M, Bertens LF, Bitter W, Debrujin JD, Champagne DL, Cuppen E, Fikl G, Vandenbroucke-Grauls CM, Janssen RA (2009) Zebrafish development and regeneration: new tools for biomedical research. Int J Dev Biol 53(5-6):835–892. https://doi.org/10.1387/ijdb.082615sb
10. Hõlttä-Vuori M, Salo VT, Brackmann C, Enejder A, Panula P, Ikonen E (2010) Zebrafish: gaining popularity in lipid research. Biochem J 429(2):235–242. https://doi.org/10.1042/BJ20100029
11. Oka T, Nishimura Y, Wang Z, Nishiyama T, Shimada Y, Yang Z, Uremoto N, Kuroyanagi J, Nishimura N, Tanaka T (2010) Diet-induced obesity in zebrafish shares common pathophysiological pathways with mammalian obesity. BMC Physiol 10(1):21 https://doi.org/10.1186/1472-6793-10-21
12. Lagunin A, Ivanov S, Rudik A, Filimonov D, Porokov V (2013) DIGEP-Pred: web service for in silico prediction of drug-induced gene expression profiles based on structural formula. Bioinformatics 29(16):2062–2063. https://doi.org/10.1093/bioinformatics/btt322
13. Sakmarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, Jensen LJ, von Mering C (2017) STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res 45(Database issue):D362–D368. https://doi.org/10.1093/nar/gkw937
14. Liu T, Lin Y, Wen X, Jonisson RN, Gilson MK (2007) BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res 35(Database issue):198-201. https://doi.org/10.1093/nar/gkl999
15. Ho JC, Hsiao CD, Kawakami K, William KF (2016) Triclosan (TCS) exposure impairs lipid metabolism in zebrafish embryos. Aquat Toxicol 173(2):39–35. https://doi.org/10.1016/j.aquatox.2016.01.001
16. Makky K, Duvvijap K, Pramanik K, Ramchandran R, Mayer AN (2008) A whole-animal microplate assay for metabolic rate using zebrafish. J Biomed Screen 13(10):960–967. https://doi.org/10.1177/1087579X08326580
17. Mathews J, Newcomer JW, Mathews JR, Fales CL, Pierce KJ, Akers BK, Marcu I, Barch DM (2012) Neural correlates of weight gain with olanzapine. Arch Gen Psychiatry 69(12):1226–1237. https://doi.org/10.1001/archgenpsychiatry.2012.994
18. Parekh S, Anania FA (2007) Abnormal lipid and glucose metabolism in obesity: implications for non-alcoholic fatty liver disease. Gastroenterology 132(6):2191–2207. https://doi.org/10.1053/j.gastro.2007.03.055
19. Consitt LA, Bell JA, Houmard JA (2009) Intramuscular lipid metabolism, insulin action, and obesity. JUWEBM life 61(147–55. https://doi.org/10.1002/iub.142
20. Ni Y, Zhao L, Yu H, Ma X, Bao Y, Rajani C, Loo LW, Shvetsov YB, Yu H, Chen T, Zhang Y (2015) Circulating unsaturated fatty acids delineate the metabolic status of obese individuals. EBiomedicine 2(10):1515–1522. https://doi.org/10.1016/j.ebiomed.2015.09.004
21. Ebbert JO, Jensen MD (2013) Fat depots, free fatty acids, and dyslipidemia. Nutrients 5(2):498–508. https://doi.org/10.3390/nu5020498
22. Choi MS, Kim YJ, Kwon EY, Ryoo JY, Kim SR, Jung UJ (2015) High-fat diet decreases energy expenditure and expression of genes controlling lipid metabolism, mitochondrial function and skeletal system development in the adipose tissue, along with increased expression of extracellular matrix remodelling-and inflammation-related genes. Br J Nutr 113(6):867–877. https://doi.org/10.1017/S0007114515000100
23. Wone BW, Donovan ER, Cushman JC, Hayes JP (2013) Metabolic rates associated with membrane fatty acids in mice selected for increased
maximal metabolic rate. Comp Biochem Physiol A Mol Integr Physiol 165(1): 70–78. https://doi.org/10.1016/j.cbpa.2013.02.010
24. Heindel JJ, Blumberg B, Cave M, Machtinger R, Mantovani A, Mendez MA, Nadel A, Palanza P, Panzica G, Sargis R, Vandenberg LN (2017) Metabolism disrupting chemicals and metabolic disorders. Reprod Toxicol 68:3–33. https://doi.org/10.1016/j.reprotox.2016.10.001
25. Weber JM (2011) Metabolic fuels: regulating fluxes to select mix. J Exp Biol 214(Pt 2):286–294. https://doi.org/10.1242/jeb.047050
26. Parameswaran K, Todd DC, Soth M (2006) Altered respiratory physiology in obesity. Can Respir J 13(4):203–210. https://doi.org/10.1155/2006/834786
27. Melo LC, Silva MA, Calles AC (2014) Obesity and lung function: a systematic review. Einstein (Sao Paulo). 12(1):120–125 https://doi.org/10.1590/S1679-45082014R4W2691
28. Porhomayon J, Papadakos P, Singh A, Nader ND (2011) Alteration in respiratory physiology in obesity for anesthesia-critical care physician. HSR Proc Intensive Care Cardiovasc Anesth 3(2):109–118 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3484623/pdf/hsrp-03-109.pdf
29. Salome CM, King GG, Berend N (2009) Physiology of obesity and effects on lung function. J Appl Physiol 108:206–211. https://doi.org/10.1152/japplphysiol.00694.2009
30. Khanal P (2019) Patil BM. Gene set enrichment analysis of alpha-glucosidase inhibitors from Ficus benghalensis Asian Pac J Trop Biomed 9:263–270. https://doi.org/10.4103/2221-1691.260399
31. Khanal P, Patil BM, Mandar BK, Dey YN, Duyu T (2019) Network pharmacology-based assessment to elucidate the molecular mechanism of anti-diabetic action of Tinospora cordifolia. Clin Phytosci 5:35. https://doi.org/10.1186/s40816-019-0131-1

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.